COMP <GO>
TRLV vs CRON // GROSS PROFIT MARGIN
Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE) VS. Cronos Group Inc. Common Share (NASDAQ) • 15-METRIC TALLY: TRLV 5
— CRON 4
▲ GROSS PROFIT MARGIN LEADER: TRLV
LAST: $10.28 (-3.02%) • MKT CAP: $2.04B
gross-margins
60.20%
LAST: $3.30 (-1.79%) • MKT CAP: $1.24B
gross-margins
42.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TRLV VS. CRON)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TRLV | CRON | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 60.20% | 42.80% | +17.40 | TRLV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | -4.50% | +17.30 | TRLV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.9x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 11.20% | 0.01% | +11.19 | TRLV | /fcf-yield <GO> |
| Operating Margin | 12.10% | -11.90% | +24.00 | TRLV | /operating-margins <GO> |
| Net Profit Margin | -9.90% | -2.00% | -7.90 | CRON | /net-margins <GO> |
| Revenue Growth (YoY) | -0.40% | 24.60% | -25.00 | CRON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.12 | 15.20 | -14.08 | CRON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 6/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 55.0 | -6.70 | CRON | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.04B | $1.24B | $803.3M | TRLV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TRLV REV | CRON REV | TRLV GROSS % | CRON GROSS % | TRLV FCF | CRON FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.18B | $146.6M | 60.2% | 42.8% | $228.6M | $149.0K |
| FY 2024 | $1.19B | $117.6M | 60.3% | 21.4% | $148.9M | $6.4M |
| FY 2023 | $1.13B | $87.2M | — | — | $201.8M | -$42.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TRLV // BETA —
CRON // BETA —